THOMAS THUM,JOHANN BAUERSACHS,STEFAN ENGELHARDT,CARINA GROSS
申请号：
MX2011012838
公开号：
MX336299B
申请日:
2009.02.26
申请国别(地区):
MX
年份:
2016
代理人:
摘要：
The present invention relates to a promoter region of a microRNA, the use of a microRNA, in particular miR-21, and related elements for the diagnosis and for the manufacture of a medicament for the treatment and/or prevention of fibrosis and/or fibrosis related diseases. Additionally, the invention concerns antisense oligonucleotides against targets of miR-21. A cell deficient for miR-21, the promoter region and targets of miR-21 and a knock-out organism thereof are also encompassed. Finally, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.La presente invención se refiere a un compuesto caracterizado porque comprende un aligonucleótido modificado que consiste de 12 a 30 nucleósidos ligados, en donde el oligonucleótido modificado comprende una secuencia de nucleobase complementaria a miR-21 o un precursor del mismo, para uso en el diagnóstico fibrosis o un trastorno fibroproliferativo en un sujeto.
